BCTX
HEALTHCAREBriaCell Therapeutics Corp - New
$4.15+0.08 (+1.97%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BCTX Today?
No stock-specific AI insight has been generated for BCTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.60$37.20
$4.15
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-14.42
Dividend Yield—
Dividend / Share—
ROE-1.8%
Profit Margin—
Debt / Equity—
Trading
Volume204K
Avg Volume (10D)—
Shares Outstanding7.3M
BCTX News
20 articles- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyYahoo Finance·May 7, 2026
- BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a StudyYahoo Finance·May 6, 2026
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast CancerYahoo Finance·May 6, 2026
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026Yahoo Finance·Apr 27, 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer ModelsYahoo Finance·Apr 21, 2026
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR MeetingYahoo Finance·Apr 20, 2026
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 LicenseYahoo Finance·Mar 31, 2026
- BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR ConferenceYahoo Finance·Mar 18, 2026
- BriaCell to Present Four Poster Presentations at the 2026 AACR Annual MeetingYahoo Finance·Mar 10, 2026
- BriaCell Therapeutics Corp. Announces Results of Shareholder MeetingYahoo Finance·Mar 5, 2026
- BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 LicenseYahoo Finance·Feb 18, 2026
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerYahoo Finance·Feb 17, 2026
- BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationYahoo Finance·Jan 28, 2026
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsYahoo Finance·Jan 27, 2026
- BriaCell Therapeutics Announces Closing of US$30 million Public OfferingYahoo Finance·Jan 15, 2026
- Top Midday DeclinersYahoo Finance·Jan 14, 2026
- Big Bank Earnings, Inflation Data in Focus as US Equity Futures Slip Pre-BellYahoo Finance·Jan 14, 2026
- BriaCell Therapeutics Announces Pricing of $30 million Public OfferingYahoo Finance·Jan 14, 2026
- Top Midday GainersYahoo Finance·Jan 13, 2026
- BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ PatientYahoo Finance·Jan 13, 2026
All 20 articles loaded
Price Data
Open$4.17
Previous Close$4.07
Day High$4.23
Day Low$4.11
52 Week High$37.20
52 Week Low$3.60
52-Week Range
$3.60$37.20
$4.15
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-14.42
Dividend Yield—
Dividend / Share—
ROE-1.8%
Profit Margin—
Debt / Equity—
Trading
Volume204K
Avg Volume (10D)—
Shares Outstanding7.3M
About BriaCell Therapeutics Corp - New
BriaCell Therapeutics Corp. The company is headquartered in West Vancouver, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—